Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BerGenBio ASA ( (BRRGF) ) has issued an announcement.
Oncoinvent ASA, a clinical-stage radiopharmaceutical company listed on the Oslo Stock Exchange, is developing its lead candidate Radspherin® for the local treatment of cancer spread within body cavities, supported by early clinical data showing encouraging efficacy and a favorable safety profile, and produced from its dedicated manufacturing facility in Oslo. The company’s board has launched a value-neutral replacement share option and RSU program following its merger with BerGenBio and has granted a total of 6.36 million replacement options and 25.77 million new options—together representing 6.7% of fully diluted shares—with significant allocations to senior management and board members at a strike price aligned with the market, underscoring the use of equity incentives to align insiders with shareholders and to support long-term talent retention in a competitive biotech sector.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
Oncoinvent ASA is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies for solid cancers. Its lead product candidate, Radspherin®, is an investigational alpha-emitting radiopharmaceutical using radium-224-loaded calcium carbonate microparticles to target micro-metastases locally in body cavities after surgery, particularly peritoneal carcinomatosis from ovarian and colorectal cancer. The company is running a clinical development program that includes a completed Phase 1 trial, a completed Phase 1/2a trial, and an ongoing randomized Phase 2 trial across the US, UK and Europe, supported by in-house manufacturing capabilities in Oslo and a listing on the Oslo Stock Exchange.
YTD Price Performance: -91.03%
Average Trading Volume: 936,977
Current Market Cap: NOK210.5M
Find detailed analytics on BRRGF stock on TipRanks’ Stock Analysis page.